Moxifloxacin Hexal

Moxifloxacin, the active ingredient in Moxifloxacin Hexal, is a fluoroquinolone presented as an oral dosage form for systemic use. It treats a range of bacterial infections, including respiratory and skin infections, in adult patients when prescribed by a qualified health professional.

GNH USA supplies Moxifloxacin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and consistent product availability across multiple markets.

Moxifloxacin is indicated for several bacterial infections affecting the respiratory tract and skin.

Community-acquired bacterial pneumonia: effective treatment of infection caused by susceptible Streptococcus pneumoniae and other typical pathogens. Acute bacterial sinusitis: reduces symptoms and bacterial load in patients with acute sinus inflammation. Acute bacterial exacerbations of chronic bronchitis: shortens duration and severity of flare‑ups in chronic bronchitis patients. Skin and skin structure infections: resolves cellulitis, abscesses and other soft‑tissue infections caused by susceptible organisms. Severe urinary tract infections: provides bactericidal activity against common uropathogens.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset that may resolve without treatment. - Diarrhea: loose stools that are usually self‑limiting. - Headache: transient head pain occurring during therapy. - Dizziness: sensation of light‑headedness, often temporary. - Taste disturbance: altered taste perception that usually resolves after therapy.

Serious or Rare Side Effects: - Tendon rupture or inflammation: risk of tendon damage, especially in older patients or those on steroids. - QT interval prolongation: may cause abnormal heart rhythm, requiring ECG monitoring in at‑risk individuals. - Severe allergic reactions (anaphylaxis): rapid onset of hives, swelling, breathing difficulty. - Clostridioides difficile‑associated diarrhea: severe colitis presenting with watery stools and abdominal pain.

When prescribing Moxifloxacin, clinicians should consider several safety considerations.

Renal impairment: dose may need adjustment and renal function should be monitored. Hepatic dysfunction: liver enzymes should be checked before and during therapy. History of tendon disorders: avoid use in patients with prior tendon injury or concurrent corticosteroid therapy. QT prolongation risk: caution in patients with cardiac arrhythmias, electrolyte imbalance, or other QT‑prolonging drugs. Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. Store below 25°C: keep in the original pack, protect from moisture.

Moxifloxacin can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of moxifloxacin, decreasing its efficacy. - Warfarin: may increase anticoagulant effect, requiring closer INR monitoring. - Theophylline: may raise plasma levels, increasing risk of toxicity.

Moderate Interactions (Monitor Closely): - Corticosteroids: combined use may raise tendon rupture risk. - NSAIDs: may increase central nervous system stimulation, causing dizziness or seizures.